skip to search skip to navigation skip to main content

Archive: February 2017

GenomeDx Announces Research Collaboration with Astellas to Identify Genomic Drivers of Patient Response to XTANDI® (enzalutamide) Capsules

13th February 2017 in Other activities

San Diego, January 2017 – Astellas in collaboration with GenomeDx Biosciences announced that it has entered into a research collaboration to apply genomic tumor profiling using GenomeDx’s Decipher® Classifier and Decipher GRID® as a potential aid in the identification of prostate cancer patients undergoing active surveillance who may benefit from treatment with XTANDI® (enzalutamide). As…

Read Full Post

Privacy Policy  |  Terms of Use  |  Cookies PolicyCopyright © 2018 Astellas Pharma